Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Digital health)

Innovation 'Elevator Pitch':
A web based solution addressing some major pain points for Health and Social Care - Cost Savings, visibility of available beds, A&E congestion, Delayed transfer of Care (DToC). We also provide a single Command & Control Centre for Major Incidents
Overview of Innovation:
Our  web solution offers:
Real-time visibility of available beds: For all care Professionala across multiple care domains and a wide geographical area, including Hosoitals, Trusts, Boroughs and event Social Care block bookd beds. A search for any bed type across across any care domain in a city, region or entire country yields results in a matter of seconds.

A&E: : Visibility of volumes waiting in A&E, their individual waiting times/times to breach and the ability to Triage score each and every one of them. From this, A&E departments can at least make informed decisions and prioritise well in advance of any bed availability issues.

Early warning system: Thresholds maybe set by hospital management, particularly around A&E, Emergency and Acute bed types. These thresholds are then monitored in real-time by our solution, without any additional user intervention. An algorithm we created takes these thresholds and compares them with existing bed levels in order to provide an overall, colour coded hospital status indicator in line with the recent OPEL standard (NHS England 2016). This status indicator also provides colour coded status for each of these key bed types. Simply put it is an early warning system available for every care professional in the hospital setting so that they can all see where pressures are quietly building and take a more proactive approach to hospital status before a crisis occurs.

Outside the hospital: To assist those in search of available beds, such as bed managers from other hospitals, GP’s and other care professional, our solution also provides a high-level view of a hospital’s current status to this wider audience. This approach makes clear whether a hospital or hospitals are currently experiencing difficulties and thus reduce the chance of blindly picking up the phone or making e-mail enquiries on available beds to a hospital that is already struggling.

Dynamic sitrep: Removes the need for lengthy update meetings. Sitrep++ provides real-time admit/discahrge information instantly.

DToC: Identifies DToC the moment they occur and offers a collaborative approach for both Health and Social Care to manage and reduce DToC via a single interface, We provide full cost and delay duration/impact stats in realtime too, thus removing the overhead from the individual.

Major Incidents: Our Command & Control Centre feature allows co-ordination of multiple A&E's across an entire city via a single interface.

Our feature rich solution does much more.
 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption
Benefit to NHS:
A&E congestion and waiting times: Just a 10% reduction in A&E breaches means that around 33,000 patients, per year, would wait less time to receive the appropriate level of care.

Delayed Discharge: A mere 5% reduction in DToC 'Bed Blocking' means a £45m per year saving for NHS alone. That's a reduction of 78,000 delay days; meaning that 6000 more people could receive treatment with the same bed count and less effort. The reduction in managing and reporting overheads for both Health and Social Care are also significant.

Efficiency: Precious time spent on day to day administration for both Heath and Social Care is enormous. Entry of the same information over and over again, manually counting available beds in times of crisis, bed managers glued to the telephone dealing with inquiries and multiple sitrep meetings, each slowly grinding care professionals into the ground. In these areas NHS and Social Care could realise a 90% reduction in effort/time. In a potulation of 200 GP's and 200 bed Managers that equates to circa £8m year on year. GP's couuld locate an approapraite 'available' bed for their patient in seconds without a single e-mail or phone call. Social Care would be able to locate and Block booked bed or Care home bed anywhere in the country in seconds

Command & Control Centre:  I the event of a Major Incident - A single Command & Control enables NHS to manage/co-ordinate multiple hopsital locations from a single interface and direct Ambulance Servcies more efficiently.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
A&E congestion and waiting times: Just a 10% reduction in A&E breaches means that around 33,000 patients, per year, would wait less time to receive the appropriate level of care.

Delayed Discharge: A mere 5% reduction means a £45m per year saving for NHS. That's a reduction of 78,000 delay days; meaning that 6000 more people could receive treatment with the same bed count and less effort.
 
Current and planned activity: 
We are trying to gain traction with both NHS and Social Care which is notoriously difficult. Our planned activity is to engage with a number of key hospitals and boroughs to showcse our solution. This is the area where we require support in securing the inital contacts and interst in NHS/Social Care.
What is the intellectual property status of your innovation?:
We have the intellectual property of our solution already secured.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Regional Scalability:
By design, a web based application is built to scale and is available via the usual suite of internet browsers.
Scaling across West Midlands: expected user footprint is circa 250 'concurrent' users
based on 19 Acute, 6 Mental Health, 1 Ambulance trust/s and 7 Social Care boroughs.
Measures:
Outcome: Greater efficiency within Hospitals:
Measure: Before and after comparison on visibility of available beds - quality and cost/time saving
Measure: Impact upon Patient flow
Measure: Impact upon A&E volumes, breaches and management effort. for time/cost saving.
Measure: Before and after DToC volumes, management and reporting effort on time/cost saving
Measure: Cost/time saving v cost of solution
Measure: feedback on impact of application wrt visiblity and ease of use.
Measure: Patient feedback

Outcome: Greater efficiency for Social Care
Measure: Before and after levels of visibility and availability of block-booked or normal care home beds
Measure: Before and after DToC volumes, management and reporting effort
Measure: Care Professional feedback

Outcome: Patient satisfaction
Measure: A&E waiting times and volumes
Adoption target:
Adoption Target: All Acute, Mental Health and Ambulance Trusts in the region.
Minimum viability: 4 Major hospitals in the region along with corresponding Social Care boroughs.
Read more
Hide details
Paul Rylance 16/06/2017 - 18:04 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Reduce bedblocking and improve ward care by enabling ward access to digital data upon admission of personal knowledge of the patient including This Is Me, My Passport and Risk data, and assist with stepdown process and therapy
Overview of Innovation:
ReMe supports dementia, older people, carers and families and accompanies the person across their care journey. ReMe was trialled and co-produced by dom care, care homes and in wards.
A new breed, we’ve christened ReMe ‘Activity Based’ software, to differentiate from care planning. For patient knowledge and the ability to enhance care comes from activities, not data input. By using algorithms to source bespoke internet images, music and videos and define a profile it’s possible to deliver more person-centred care. At ReMe’s core are activity tools that learn about the person, such as reminiscence and cognitive therapy, and enable discovering calming content for acute care strategies. ReMe stores life stories, preferences and interests and connects with a care circle, as well as creating automated activity reports which can be sent to the user's family.
Around this person-centred care core are business tools each care sector’s needs. Therefore, ReMe achieves an ROI by assisting in client acquisition, care assessment, acute care planning, management and paper reduction, activity creation, scheduling and data collation, whilst providing family and admin reporting. With cross care sector data connectivity and real portability, ReMe becomes part of a dementia acute care strategy.
For care in the community, ReMe’s free with premium subscriber services. With self-management, connectivity, entertainment and activities and by generating data, ReMe supports daily care, celebrates a life, strengthens family links and tackles agitation, depression and isolation, becoming a highly-personalised resource and recourse.
ReMe is used currently in the following care sectors.
For dom care, ReMe improves care, client engagement, reports and generates extra revenue through selling extra hours based on a wellbeing and family connected value added service.
For care homes, ReMe helps families engage in the care process, carers use tablets productively, reduces paper and enhances activities, therapy and reporting. ReMe improves care and saves money.
For hospitals, ReMe is a low-cost means to better know the patient; that improves admission, through digital connection to the care home and dom carer providing access to knowledge of the patients’ ‘day before’ care profile. ReMe enhances person centred care, patient wellbeing, reporting and stepdown.
ReMe is easily adopted with no legacy software or training needs.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
RemindMeCare (ReMe) delivers savings for the NHS through its care in the community self-management functionality reducing admissions, an improved admissions process (i.e. Digital This Is Me, Risk and My Health Passport), enhanced in-ward care, reduced medication and more informed step down.
 
ReMe provides connectivity with care homes, domiciliary care, day care centres and families, and enables better knowledge of the person to be used in person-centred care delivery.
 
Continuity of bespoke, tech advanced activities and therapies, that enhance patient wellbeing, engagement, person centred care and acute dementia care, generate improved patient outcomes, reduced agitation, medication and drugs costs, as well as better informed step down and earlier discharge.
 
Increased availability of personal and risk data reduces risk (and possibly litigation), resort to medication and wellbeing decline, so ReMe aims to reduce bed days.
 
ReMe supports improved family visits and overnight stays through the provision of familiar content and entertainment.
 
Automatic care activities recording, for CQC/admin reporting and research is available.
 
Evidence of value is shown only by the demand and positive feedback received from care homes, LA’s, hospitals and families nationwide but will be formalised shortly.
 
ReMe addresses the Next Steps NHS Five Year Forward View; by reducing A&E/GP visits, making patients information available to clinicians; enabling prescribing apps to help people manage their own health, addressing loneliness and aiding carer respite and assisting LA requirements regarding services provision and monitoring.
 
We’re pioneering this connected care approach in conjunction with SWLCC 5-year strategy, focussing on care quality, safety and cost savings, addressing the defined challenges of avoiding hospital admission, supporting ‘Community services to meet the highest standards and working more closely with primary care, mental health, acute hospital services and social care’. Our participation in the Better Care funded Croydon APA project defines ReMe’s role in the budget shift from hospitals to the integration of health and social care, through the coordination of care. Critically, ReMe addresses recommendations by NICE to focus on person centred and family care support through engaging consumers with a user-friendly product that promotes self-management of illness including long term conditions.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
RemindMeCare delivers support for older people and people with dementia, their carers and families and which is portable and usable by their carers, from home to domiciliary, live-in, day care, residential and ward care. ReMe was developed with people in the NHS and trialled in wards and care homes.
ReMe is a new breed we’ve christened ‘Activity Based’ software to differentiate itself from care planning software. For knowledge of the person and the ability to enhance care is derived from activity provision, not from data input.
By providing self-management tools and engaging activities and by generating data, ReMe supports daily care, celebrates a life, strengthens links with family and tackles agitation, depression and isolation. ReMe becomes a daily highly personalised resource and recourse for those people involved in care.
ReMe’s suite of person-centred care algorithm based activity tools enhance care and are the constant core across all care sectors, and continually learn about the person wherever they may be. ReMe’s the only system that offers bespoke reminiscence and cognitive therapy by sourcing images, music and videos that are unique to the user and so enables discovering calming content for acute care strategies. ReMe stores life stories, preferences and interests with carers and a care circle, as well as creating automated activity reports which can be sent to the user's family.
Wrapped around this person-centred care core are business tools that address the needs of each care sector encountered by the person, including those common to all such as CQC reporting and family engagement.
RemindMeCare goes further, achieving an ROI for care businesses and wards by assisting in care assessment, acute care planning, management and paper reduction, activity creation/scheduling/planning and data collation, whilst providing family, admin and regulatory body reporting. With cross care sector data connectivity and real portability, ReMe becomes part of a dementia acute care strategy for whichever care sector at any time is caring for the person. For the ward, ReMe offers access to the vital knowledge of ‘the day before’ care profile of the admitted patient and the benefits that enhanced person centred care can deliver.
Usable on any platform and with encrypted data, ico compliance (G Cloud pending), ReMe has addressed information governance and digital security.
Please view videos (https://www.remindmecare.com/business/ward/ )
Current and planned activity: 
ReMeApp: self-management care tools that assist maintain care in the community, improve the ability of carers to deliver bespoke care and connect the person with their care circle and with their community; to reduce resort to GP and A&E through enhanced care circle engagement. Dementia care training is included and partnerships with Dementia Pathfinders and Worcester University will be extended achieve delivery.
ReMeData: Integration with Care Planning systems; ie with patient’s systems (such as CMC) and others as required.ReMeGP:  GP Connectivity. Through remote connectivity tools GP’s can remain engaged, be better informed but on a remote basis. The intended result is less resort to disturbing surgery visits. GP connectivity will be release in 2018.
ReMeComm: self-management care tools for those cared for in the community, that match the person cared for with local community activities (A partnership pending with Worcester University, CarersUK, MeetingDem and others. 
What is the intellectual property status of your innovation?:
We are the sole owners of our IP
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Simon Hooper 13/05/2017 - 20:13 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early  stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.
 
Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]
 
HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.
 
HeartFlow has received CE mark approval for use in UK/Europe.  CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The use of HeartFlow FFRct can improve patient care, efficiency, and lower medical costs:

Patient Care
  • HeartFlow FFRct provides a physician with both functional and anatomical data, improving diagnostic accuracy, thus reducing invasive procedures and associated complications
  • Improved diagnostic accuracy improves patient care and quality of life
  • Studies suggest that incorporating FFRct lowers patient radiation levels due to decreased angiography
Efficiency
  • Studies indicate that the application of FFRct may result in a reduction of unnecessary angiographies, improved cath lab efficiency, and reduced waiting lists
  • By providing both functional and anatomic data, physicians may be able to reduce the need for and waiting times associated with other diagnostic imaging tests
Cost of Care
  • As demonstrated in the NICE guidance, the use of HeartFlow FFRct can potentially reduce the cost of care. NICE estimates an average savings of £214 per patient. This saving is based on not conducting inappropriate invasive diagnostics.
  • A Japanese study has indicated that the use of the CCTA-FFRct strategy to select patients for Percutaneous Coronary Intervention (PCI) would result in 32 % lower costs and 19 % fewer cardiac events in 1 year compared to the most commonly used CAG-visual strategies. 
 
“The HeartFlow FFRct Analysis provides a definitive understanding of both anatomical and functional findings, without any additional testing or risk for patients. Application of the HeartFlow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”
  -  Dr. Joseph Mills, Liverpoool Heart and Chest Hospital
Online Discussion Rating
6.00 (2 ratings)
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As stated in the NICE guidance, the adoption of HeartFlow FFRct in the West Midlands region could improve patient care and outcomes while generating significant savings for the region.
 
We are looking for additional adoption sites and would be interested in hearing from West Midlands Trusts that would like to take the lead in establishing our UK user group.  
Current and planned activity: 
HeartFlow is in early conversations with NHS Trusts and commissioners. A handful of early adopting NHS medical centres have begun to provide HeartFlow FFRct for their patients. HeartFlow is engaging with interested physicians at centres with high quality CT capabilities.

UK Sites where Heartflow FFRct is being used:
  • St. Bartholomew’s Hospital (London)
  • Liverpool Heart and Chest
  • Russell Hall Hospital (Dudley, West Midlands)
  • Freeman Hospital (Newcastle)
HeartFlow is in discussion with other UK site about adoption of FFRct.

Planned / required activity
  • We are looking for additional adoption sites and would be interested in hearing from Trusts that would like to take the lead in establishing our UK user group 
  • Whilst we have undertaken worldwide studies we are always interested in ongoing evaluation / validation and collaborative developments technically and with clinical pathway integration.
  • In the future we plan on conducting clinical trials based & focused on specifically the UK population.
What is the intellectual property status of your innovation?:
HeartFlow has established significant intellectual property and has been issued several patents.
HeartFlow received CE IIA mark approval for use in UK/Europe in July 2011. The technology is also ISO 13485 certified.  

Return on Investment
Savings have been demonstrated in clinical trials (PLATFORM), third party health economic modelling (NICE guidance, Int’l Journal of Cariology 183 (2015) 173-7), and real world experience at early adopting centres.
 
NICE recommendations for Heartflow FFRct (February 2017) state:  “Using HeartFlow FFRct may lead to cost savings of £214 per patient. By adopting this technology the NHS in England may save a minimum of £9.1 million (annually) by 2022 by avoiding invasive investigation and treatment.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
Liverpool Heart and Chest has performed more HeartFlow analyses than any other site. They have demonstrated clinical and economic benefits to incorporating HeartFlow FFRct into their practice. The uptake is due in part to to the strong support from their regional CCG.
Measures:
HeartFlow is seeking to achieve the following outcomes:
 - Improved patient care: Reduction in unnecessary invasive angiographies and eventually a reduction in waiting times for those patients that need angiographies
 - Reduction in Healthcare Costs: NICE estimates cost savings of 214 GBP per patient. We are working with existing sites to demonstrate real world outcomes.
 - Quality of Life: HeartFlow's clinical utility trial, PLATFORM, demonstrated an improvement in quality of life when FFRct was incorporated into patient care pathways. It is likely that this is in part due to the avoidance of unnecessary interventions. To date we have not seen any adverse events from avoiding invasive procedures.   
Adoption target:
NICE estimates cost savings of 9.1M GBP annually within five years. To reach this objective approximately 35,000 patients would need to have access to a HeartFlow FFRct analysis. 
Read more
Hide details
Ben Forrest 12/05/2017 - 16:12 Screening 2 comments
Innovation 'Elevator Pitch':
Radar supports health and social care organisations in holistically managing all aspects of their quality and compliance activity, whether intuitively building a CQC evidence portfolio or managing audit, incidents and risk.
Overview of Innovation:
Radar Healthcare system has been developed using the latest technologies and platforms to ensure a cutting edge and sustainable solution. The system adopts proven business rules in use across the health & social care sector in the UK and incorporates the Care Quality Commission (CQC) guidelines and procedures.
 
Radar Healthcare from Smartgate Solutions has been developed in partnership with knowledgeable and respected healthcare professionals. The system is scalable and configurable to organisational needs to meet both internal and regulatory requirements.

The Radar Healthcare modules help care providers meet their daily operational challenges and associated quality and compliance requirements. 
 
Radar supports organisations by: Taking the worry out of quality & compliance
  • A responsive system, allowing you to visualise and manage risk, training and regulatory compliance across the business domain.
Gain a clear line of sight into performance
  • Intuitive and dynamic dashboards providing real-time visibility of business performance at both location and organisational levels.


Automation of key procedures for operational efficiency
  • Translating business rules and SOP’s into action through our automated workflows and action tracking.
Reduce costs
  • Supporting a systems approach delivering demonstrable ROI across business resources, time and staffing.
 Radar Healthcare is currently in use across multiple service areas including Social Care, Primary Care, Specialist Clinics, Acute Care  and Patient Transport.
 
It’s primary purpose is to assist in ensuring each organisation meets relevant regulatory compliance standards and support organisations reduce duplication and effort in managing that process.
 
It will allow existing processes and procedures to be followed more efficiently and enable the introduction of new processes and procedures that are currently unfeasible with existing systems.
 
Key Facts
  • The system is made up of specific modules, each providing a range of functions that can support organisations in their daily operational activity.
  • All Modules work collaboratively and share data to avoid duplication.
  • Data can be integrated from various sources and other software system.
  • Dashboards and reports can be viewed and created by employees, by department, by directorate or as an entire organisation.
  • Each module has the ability to accommodate pre-configured workflows aligned to your existing SOPs, policies and procedures.
 www.smartgatesolutions.co.uk
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Wealth creation / Digital health
Benefit to NHS:
Radar Healthcare modules have been developed to help care providers meet their daily operational challenges and associated regulatory requirements. 
 
Adopting proven tool kits and processes, Radar Healthcare ensures compliance with the essential standards relating to the quality and safety of care as defined within the CQC and other regulatory bodies.
 
Cost Improvement (CIP) Opportunities
The CIP opportunities are variable and based upon the modules selected. Efficiency savings are realised through two specific means:
  1. Replacement of existing systems in use across the organisation
  2. Redeployment of posts supporting quality and compliance management and re-deploying skills to vacancies within the organisation
 
A high level simulation exercise exploring how the implementation of Radar could support the reduction of cost within an NHS Hospital in the North of England (approximately 3,500 staff serving a population of c250,000 people) identified potential savings of over £300,000 over a 3 year period.
 
Smartgate Solutions have developed a cost calculator capable of identifying cost against current systems and workforce requirements.
 
Efficiency Savings
Additional efficiency improvements can be realised through:
  • Ensuring compliance with CQUIN targets or other commissioning KPIs
  • Improved efficiency and productivity in managing quality and compliance activity
  • Smartgate can support organisations with their recruitment processes and reduce the time spent undertaking training post employment. Radar allows you to issue training and development content to employees prior to their engagement and for completion online, effectively tracking and monitoring their progress against the training content.
  • Reducing the time spend responding to requests from regulatory bodies and building evidence portfolios. Radar supports the on-going development of evidence portfolios, providing clear audit trails and concise reporting.
  • The system intuitively allows users and organisations to share information, allocate tasks and distribute vital information in real time. It provides a safe and effective way of sharing learning and information.
 Client Testimonial
“We are committed to delivering the highest levels of service and CQC compliance. Radar Healthcare has been the key factor in achieving and exceeding these goals.“
John Butterfield, CEO, ER Systems
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Radar supports providers and commissioners of health and care services to effectively manage and monitor their quality and compliance expectations, deliverables and regulatory requirements with greater efficiency and often with greater effectiveness.
 
Radar enables organisations to re-deploy their scarce resources to focus on the delivery of care, freeing clinical expertise from administrative activities. 
Current and planned activity: 
Current NHS Activity:
Radar is currently utilised by numerous providers of health and care services, many of which provide NHS services.
 
We are currently engaged in discussions with both CCGs and NHS Foundation Trusts.
 
At present we are exploring opportunities to grow our engagement with NHS organisations and are seeking support and guidance from colleagues at WMAHSN, Medilink WM and the wider regional health and social care communities.

Planned/required activity:
  • Procurement / Adoption of: -  Growth and increased adoption of Radar across NHS provider and commissioner organisations  
  • Partnership: We are interested in exploring partnership opportunities with NHS organisations that may help to realise a financial ROI
What is the intellectual property status of your innovation?:
All product IP is wholly owned by Smartgate Solutions Ltd
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Tom Lindley 30/03/2017 - 09:44 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
In healthcare settings, Splunk is a powerful, easy-to-use business intelligence tool that analyses real-time data from multiple sources — enabling managers to run more efficient healthcare services.
Overview of Innovation:
Unlike other business intelligence tools, Splunk is platform-agnostic and can address ‘ad hoc’, non pre-programmed questions. Converging Data Ltd provides secure, on-premise or a hybrid cloud solution that combines and analyses structured & unstructured data from multiple sources, including but not limited to HL7 data, even collecting data directly from internal data networks.
 
This data can be interpreted without the need for predefined schemas and structures, providing real-time performance monitoring across entire care pathway.
 
Converging Date Ltd has created specific healthcare applications utilising the Splunk software platform.

Splunk makes it simple to collect, analyse and maximise the value of big data generated by security systems and business applications and improve operational performance and results.

Healthcare Intelligence
Healthcare Services & Care Pathways can be visualised and analysed using the IT Health Intelligence solution & HIX (HL7 Health Intelligence Connector).
 
Gathering data from multiple sources, in different formats and without consistent standards is what Splunk does best. HIX takes HL7 data from PAS, Pathology, Pharmacy or Electronic Health Records and provide a clear picture of how care is being delivered in real time.


HIX allows organisations to easily collect HL7 data commonly transferred between clinical and administration systems.
 
The Care Pathway Profiling tool allows data to be represented in a form that can be mapped to local physical or logical care pathways.  Alerting options ensure that the right people are notified when thresholds in service levels are reached.
 
Patient Flow
This powerful, easy-to-use business intelligence tool analyses real-time data from multiple sources, enabling managers to run more efficient healthcare services. By gathering existing structured and unstructured data from across the organisation Splunk allows healthcare providers to view the entire care pathway and direct resources to address rapidly changing conditions.
 
The Patient Flow module can easily be tuned to match local care pathways and service delivery models. Advanced analytics can be used to track organisation’s KPIs and highlight anomalies & identify root causes.

The Patient Flow module uses the Healthcare Common Information Model (HCIM) that ensures data received from multiple systems can be mapped to HL7 standards and local nomenclature. HCIM allows searching and reporting across systems which are interdependent, but not interconnected.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health / Patient and medicines safety
Benefit to NHS:
The use of real-time data allows resources to be more efficiently deployed and problems to be more easily identified and addressed. Our ability to deploy across existing data sources means it’s fast to deploy and can demonstrate value within days.
 
We have worked with healthcare organisations to improve operational efficiency tracking patient flow, demographic breakdown of A&E arrivals, real-time location services within healthcare organisations. This allows more to be delivered with fewer resources and equipment and services to be tracked and located more quickly.
 
We have also provided detailed reporting and analysis of operating theatre utilisation and the actual costs associated with delivery of specific procedures. The real-time nature and alerting capability means that this is no longer a retrospective view, but an up to date view of what’s happening right now within a complex organisation.
 
Our Analytics Capability can also be used to address cyber security. The Splunk platform once deployed, delivers a powerful analytics driven Security Information and Event Management (SIEM) capability.
  • Splunk is installed within the NHS, and within one of the UK’s largest private hospitals.
  • Splunk is used to support NHS Digital services such as Spine and NHS Choices. 
  • Internationally we are working with Public healthcare organisations in Australia.
 NHS Choices: ‘By using Splunk Enterprise, NHS Choices has been able to improve the service it delivers to website users. The organization is now looking at new ways to deliver value from its website data, including helping the partner team track usage of content provided to over 600 syndication partners, and building product-specific dashboards for the product owners showing detailed performance and transaction status for key areas of the site’.

www.convergingdata.com
 
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Benefits from the deployment of this technology will be realised through better utilisation of resources and the ability to view the status of the organisation in real-time.
Current and planned activity: 
Current NHS Activity:
Rotherham NHS Trust (Pathology and Laboratory Data Services) - use Splunk to collect HL7 Data and provide visibility across Pathology and Laboratory activity.

NHS Digital: Splunk is used by NHS digital to support national IT infrastructures such as Spine and NHS Choices.

Planned/Required Activity: Planning Stage
Luton & Dunstable NHS FT  - NHS Patient Flow and Capacity Management System – to provide visibility across the patient care pathway. Splunk will be used to ‘pull’ data from clinical and administrative systems from across the Trust, including HL7 Data, creating dashboards, reports and alerts to show activity and highlight bottlenecks. Deployment initially with internal systems then rolled out to 3rd party organisations who provide care.

International:
  • Middlesex Hospital USA
  • Ongoing projects with Australian Department of Health and the Australian Digital Health Authority.
  • We are also supplying analytics capabilities into one of the UK’s largest private hospitals.
What is the intellectual property status of your innovation?:
IP protection is afforded by a mix of proprietary applications with Converging Data IP in some connectors and point applications.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Neil Murphy 29/03/2017 - 14:34 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Accounts payable staffs spend up to 30% of their time responding to supplier queries. Solv.ai’s first product resolvr™ solves the problem at 10% the cost. Resolvr™ is cloud-based messaging applicationsupplier specific responses on behalf of AP teams 
Overview of Innovation:
According to the Procure to Pay Network, accounts payable departments spend up to 30% of their time responding to supplier queries. Solv.ai’s first product resolvr™ solves the problem at 10% the cost.  Resolvr™ is cloud-based messaging application that provides speedy, supplier specific responses on behalf of accounts payable teams.  We use any channel such as email, browsers like Firefox, Edge, Chrome, and any messaging application such as skype, slack, facebook, etc., so suppliers don’t have to download a new application, or sign into a new portal to use our service. 

Solv.ai aims to leverage the latest artificial intelligence technologies and apply them to business to business communication.  At solv.ai, we understand the importance of aiming high but taking sensible, practicable steps to build a launching pad for our ultimate goals.

Our first products are resolvr™ and resolvr:email™. They represent the first natural language process applications specifically designed to automate responses to suppliers on behalf of accounts payable departments. The total addressable market for resolvr™ and resolvr:email™ includes all businesses with suppliers and an accounts payable function.  This is most global B2B activity. 

The founding team are experienced procure-to-pay, e-invoicing, and digital cash experts.  We have broad and deep contacts in the industry and plan to use all of them to make Solv.ai succeed.  

The founders are very confident in the success of resolvr™, as a standalone application that competitors may emulate over time, but more importantly cross selling opporutnities for buyers to sell into suppliers can facilitate tremendous benefits between buyers and suppliers. 

Solv.ai has a co-innovation agreement with Birmingham City Universty's Centre for Cognitive Digital Systems Engineering to build out a suite of APIs as a platform for other supply chain interaction efficiencies.  This would include integration and interoperability, and enhance logistics and procurement activities. 

The immediate benefit resolvr and resolvr email can offer the NHS is reduced costs, but over time, solv.ai can help transform the trade transaction life-cycle by implementing an "AI-first" approach to procure to pay.  The NHS could be the first to employ an AI-powered communication layer that supports supplier information management, file tranformation, integration, meta-data for its communication activities with its supplier base. 





 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Wealth creation / Digital health
Benefit to NHS:
  • Up to 80% reduction in supplier queries
  • Enhanced Supplier experience; 24/7 access, immediate responses
  • Real-time, multi-channel communication with supplier base
  • Gain insight and improve external communications with reporting and analysis
  • Achieve P2P streamlining promised by existing solutions
  • Partnership approach when drafting SLA
Initial Review Rating
2.60 (2 ratings)
Benefit to WM population:
More efficient public sector activities.
Current and planned activity: 
We are not currently engaged with the NHS.
What is the intellectual property status of your innovation?:
Our technology is proprietary and we have trademarks for our company name and product name.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Anonymous 17/03/2017 - 11:29 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
SEEING WHAT OTHERS SEE, AND WHAT THEY EXPERIENCE IN THE PROCESS
Eye Control, Eye Perception, Eye Emotion
Affordable,Intelligent Digital Eyewear
Overview of Innovation:
Eye Hyper Tracking System - Smart Wearable
Viewpointsystem has developed a completely new system to measure and understand human perception through the eyes.
The Eye Hyper Tracking doesn't just capture the line of sight,but also how the person reacts to what is seen. The system in the form of smart lightweight safety rated glasses allows extremely precise measuring of observations and insights coupled with the ability to SHARE what is being seen via REMOTE LIVE STREAMING.
  • Telemedicine - A health professional can conduct or instruct a procedure with the aid of a precise hands free view.
  • Training - Any aspect of training can be covered, be it a live event or with the ability to record 'what is seen' it can be then shared, learned from and shown as a unique prespective into the instructor or wearers' viewpoint and preception
  • Paramedic / 1st Responder - Imagine a world where an expert can see what you are looking at and give you on the spot support. Envisage a paramedic or 1st responder calling in advance to show the recieving hospital the extent or seriousness of a situation
  • Improving Results - Instructions are often given and confirmed as being understood, communication is key in getting things right first time. With a view of 'how' to carry out a instruction, in certain circumstances a person viewing your first attempt is both supportive and safe.
  • Reducing Costs - Specialists cannot be everywhere all of the time. With a live streaming function, they are only ever a click away to see what you see, thus reducing the need to travel, rebook appointments, move from place to place.
The system has truely endless possibilites. Having been in the scientific arena for a number of years it is proven to be relaible and very accurate. Our system takes the technology from the lab into the real world, being light, highly mobile and robust it is user friendly, simple and smart.

The revolution in the measurement and interpretation of human perception has truly begun.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
NHS Benefits
  • Efficiency - Simulation of scenarios for training
  • Efficiency - Centrally situated teams all viewing the same situation though the same perspective
  • Efficiency - 1st Responder / Paramedic support given, time saved when arrival at hospital, faster turnaround times
  • Efficiency - Right 1st time approach to training, supportive and inclusive
  • Efficiency - Faster turnaround times for paramedics at hospitals
  • Cost Benefit - Travel of key staff and personnel
  • Cost Benefit - Training budgets reduced to all areas
  • Cost Benefit - Specialists can support remotely, no need to always attend sites
  • Cost Benefit - Abilty to simulate a scenario or situation. Feedback could be given by instructor remotely
  • Cost Benefit - General hospital infastructure - The system is applicable to services outside of medical arena - IT support, Machinery supplier support, building support.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The system is designed to support all industries with medical being a specific area.
Our system not only enables faster, safer, most cost efficent ways of doing things, it provides an enabler to reduce time and improve effectivness.
Any improvements or cost savings can only help improve patient or colleagues healthcare, reduce waiting lists and improve services. It is also key to ensure the highly trained dedicated staff have every possible piece of equipment to help improve their working life balance and conditions.
Current and planned activity: 
Our current status is to engage with all 15 AHSN's in the UK.
Our system was only launched in UK in Sept 2016, and we have only just started to engage with the UK health sector.
We have a number of doctors, paramedics and hospitals trialing our system in Europe, and we have just engaged with a leading surgeon in USA who is keen to try our technology, as he was the first surgeon to use Google Glasses to carry out a live stream procedure.

Our primary intention is to be seen and heard by the NHS. We are keen to visit and demonstrate the system and possibilites first hand, as we are not a concept as we have an actual fully functioning system ready to use.
What is the intellectual property status of your innovation?:
We have IP on certain elements of the system.
Eye tracking is commonly adopted in VR/AR system is various guises.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Graham German 23/02/2017 - 11:14 Publish 1 comment
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Aptvision is revolutionary to the radiology sector providing a paperless & cost effective workflow.  Designed with radiology experts, practiced in-depth and customised to meet the specific needs of today’s modern & demanding radiology environment.
Overview of Innovation:
Total Radiology Solution including RIS and other innovative solutions has been designed to increase efficiency in hospitals and clinics - not just to store patients’ data. It’s unique innovation can be seen in:
  • Cost savings and increased productivity
  • Increase revenues for hospitals and clinics: web booking, schedule optimisation
  • Reduce errors and staff duties
 
Aptvision RIS is the most innovative RIS on the market offering fully paperless workflow from start to finish: eReferral letters automatically attached to the RIS, e-consent forms, Online Results, etc. Aptvision RIS also assures:
  • Electronic access to all documentation and forms
  • Quick access to all medical history
  • Fully web based, no installation - just the web browser
  • Ability to report on studies from any location without a need of installing dedicated software on individual doctor’s PC.
 
Much more than a standard RIS, Total Radiology Solution offers:
  • Fully integrated Web Booking in which patients can book their appointment like a seat on an airplane. From the clinic’s website patients can see which appointments are available for the type of exam they need and book it immediately.
  • Aptvision’s system automatically provides a call back from a clinic’s Call Centre, to verify the selected appointment and go through safety questions. The operator is prompted by the system to ask the appropriate questions.
  • This feature has reduced the 40% dropped calls rate to zero and practically eradicated no shows and errors.
  • Before the appointment, the patient receives a SMS Reminder of their visit and gains access to the Online Consent Form. They can complete it on their phone or computer before their visit day.
  • On the appointment day, patients can use Online Registration in the clinic using the interactive kiosk or tablet & without the need to stand in a long queue at the reception. They can also monitor their live updated waiting time on dedicated monitors.
  • The electronic consent form as well as all previous medical history is attached to patient’s record in Total Radiology System leading to completely Paperless Workflow. Once the appointment is completed, patient is informed with an SMS telling them their results are ready and can be viewed in the Online Results portal if this is appropriate.
  • Voice Recognition to more quickly create medical reports
  • Scan Audits to improve the quality of the reports and enable sharing of expertise.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Revenues increase
  • Across 16 clinics in Ireland we have facilitated savings of up to €600,000 per clinic through reducing no-shows, errors and through modality optimisation
  • We have also increased revenues by €2.4 million in an 18-month period through web-booking and e-referrals
 
Efficiency increase and cost reduction
Through fully paperless workflow
  • An advanced, configurable, fully integrated e-referral platform feeding actual availability of modalities
  • E-referral letters automatically attached to the RIS, e-consent forms, Online Results, etc
  • Electronic access to all documentation and forms
  • Quick access to all medical history
  • ensure scan is possible and safe for patient (availability & safety questions)
Reduction of manual processes
  • Fully business rules driven without manual intervention
  • Built-in processes for auto scheduling and bulk appointment operations
  • No re-typing of information
  • No web booking missed
  • Medical call centre takes over all calls so reception could focus on patients and their needs
  • Interactive kiosks, tablets and monitors allow patients to register online without a need to come to reception
Improved Patient satisfaction
  • Reduced waiting times for scans and results
  • Ensures patients safety and enhances patient experience at all stages of their appointments (web booking, online forms and results, SMS notifications, online registration etc.)
 
Quality improvement
Peer review feature that allows anonymous review of radiology reports by random peer
 
Better hospital/clinic management
Live updated personalized dashboards for quicker decision making and detailed reporting: revenue reports, comprehensive operations reports, etc.
 
Savings in time
  • Quick system implementation - within few days, not months
  • Easy and intuitive up and running in 30 mins
  • Improvements visible from day one
 
Existing customers have reported statistics of:
  • Modalities capacity increase of 30%
  • 1 extra scan per hour
  • 10 more booking per day
  • Reduced reporting time 20min -> 4min
  • 50 reports per day vs 15
"Aptvision is revolutionary to the radiology sector and is the key to a paperless workflow. It improves daily operations and leads to quicker reporting times and early diagnosis. My experience suggests that Aptvision RIS increases a clinic's efficiency and bottom line from day one and has been the answer to our digital problem in one step."

Prof. Michael Maher
Consultant Radiologist, Cork University Hospital
Professor of Radiology, University College Cork
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
With rapidly increasing demand for diagnostic imaging and hospital and clinics workflow heavily relying on paper and manual duties radiology providers are sometimes unable to cope with that increased demand and provide their diagnostic in efficient and timely manner which can result in patient dissatisfaction and in some cases even lost lives.

Aptvision Total Radiology Solution offers a solution that can revolutionize radiology industry by promoting efficiency and paperless workflow that increases productivity in hospitals and clinic and ultimately benefits patients and their lives.
Our innovative features can benefit patients in numerous manner including:
  • Better and quicker access to radiology
     
  • Reduced waiting times for scans and results which can save lives
     
  • Ensures patients safety and enhances patient experience at all stages of their appointments (web booking, online forms and results, SMS notifications, online registration etc.)
     
  • Quality improvement - Peer review feature that allows anonymous review of radiology reports by random peer. It improves the quality of the reports, enhances share of expertise and allows discussion of interesting cases with experts in anonymous manner. This hugely benefits patients and again helps to save lives
     
  • Make use of modern ecommerce technologies to patients
Current and planned activity: 
Aptvision has just completed the Serendip programme.

We have applied for late inclusion into supplychain RIS/PACS frameworks.

We are actively engaging with Queen's hospital (BHR hospitals trust). We have presented the system and received a very positive response and we are currently organising a full day workshop with all staff.

We are presenting shortly to Black County Alliance.

We are seeking to work in partnership with an NHS Trust to deliver an early demonstrator for the NHS.
What is the intellectual property status of your innovation?:
Full intellectual property of all applications and solutions is owned by Aptvision Ltd.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Fiona Smith 14/02/2017 - 10:23 Publish Login or Register to post comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
Stratification of patients into Risk Groups greatly enhances management of long-term conditions, COPD, Diabetes, Heart Failure, etc also supporting early discharge preventing readmissions.
Overview of Innovation:
Stratification of patients into Risk Groups, even for the same condition, greatly enhances the focus, scalability and agility in response to changing demand. Used to manage people with long term conditions such as COPD, Diabetes, Heart Failure, etc…… as well as supporting early discharge to prevent readmissions.
  1. Population-level Low-Risk Patients (75%): Free for BYO devices (smart or text message) for self-management and education. No remote monitoring but data can be shared with GP systems for access by all clinical stakeholders. Minimum cost to the NHS. Scalability is limitless. Activ8rlives4 Wellness and Food Diary App is available FOC via the App store and Google Play.
  2. Rising Risk Patients (20%): Where there is no smart phone availability or poor IT skills: CliniTouch Vie as below. Where Patients own Smartphone/Tablet and have WiFi: Activ8rlives Lung Health, Diabetes Health and others. Medical monitors could be prescribed on loan initially on early discharge (as one use case) and then transitioned to BYO Smartphones and monitors. Alternatively, they may be stepped-up by prescribing further monitors and data reviewed remotely at greater frequency.
High Risk Patients (5%): CliniTouch Vie: locked-down tablet provided with integrated 3G for connectivity, intensive monitoring, education and empowerment with integrated direct messaging and video support. Dynamic care plans and intelligent algorithms enable automatic triage for healthcare team. Fast, simple and quick to implement for the most at-risk and vulnerable of patients.

For further information contact
Kevin A. Auton, PhD, Managing Director, Aseptika Limited kevin.auton@aseptika.com www.activ8rlvies.com
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Spirit Healthcare: Leicester City CCG, combining telemonitoring, specialist nurse interventions and health coaching in COPD, demonstrated reduced admissions by 67% and also improved patient’s experience of care. http://www.magonlinelibrary.com/doi/10.12968/bjhc.2016.22.3.123
  1. 67% reduction in unscheduled admissions amongst patient cohort - multiple regression analysis revealed that CliniTouch telemonitoring (Spirit Healthcare) was the only intervention that statistically significantly (P<0.05) reduced unscheduled admissions.
  2. Overall reduction of 9.1% in all COPD admissions - despite the harsh winter of 2013/14, there was an overall reduction in all COPD admissions, easing winter pressure and bed blocking.
  3. Effective in managing re-admissions – number of admissions per head reduced from 3.13 to 1.02 per year (p<0.001). Nurse interventions required to manage patients also reduced, improving caseload management. The benefits were realised across the whole health economy. 
  4. Improved patients’ experience of care – patient feedback demonstrated higher levels of confidence, knowledge about their condition and positive behavioural change. 
Activ8rlives Lung Health (Sensor 3) telehealth reduced unplanned admissions and improves self-management. Undertaken clinical trials supporting Self-Care in Cystic Fibrosis (Papworth Hospital), COPD and Bronchiectasis (Portsmouth NHS) and on-going in Liverpool Heart and Chest Hospital for 45 COPD patients (Dr Dennis Wat and Mark Jackson, funded by NWC AHSN). Aseptika is an innovation partner for the Sheffield NHS Test Bed.
Liverpool Heart & Chest Hospital, Knowsley Respiratory Community Team. Sensor 3 self-care project allows patients with COPD to monitor and track their vital signs at home, using a secure and easy to use Lung Health 3 App, developed by Aseptika Ltd. The whole process takes approximately 12 minutes each day. The patients are provided with the equipment to allow daily measurements of blood pressure, heart rate, oxygen saturation, body weight, temperature, peak flow, FEV1 and physical activity levels. The measured data is displayed as simple charts. 
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Patients are educated and supported to interpret the data to enable improved understanding of their health status.
  1. Prevent unnecessary admissions as patients have access to 24/7 the COPD rapid response team as soon as there is any health deterioration for treatment to prevent unnecessary admission into hospital. The collected data is currently being analysed by Knowsley Respiratory Community Team.
  2. Technology improves patient’s confidence in managing their COPD. For patients who experience frequent infections and disease exacerbation, this can be a lifeline. In Liverpool 90% of participants would recommend to Friends and Family. 60% would be prepared to make a financial contribution of £300 to support costs.
Current and planned activity: 
Spirit Healthcare group of companies can now provide one of the most comprehensive range of solutions to support patients of all ages, all IT abilities, all levels of disease severity and across a wide range of disease areas: respiratory, cardiovascular, diabetes and frail elderly.

Aseptika currently have in development: (a) on-ward and home-use sputum test for Pseudomonas aeruginosa (patent protected); (b) BuddyWOTCH – a 3G connected wearable medical device (SpO2, HR, Temperature, Respiration Rate with Sit-to-Stand and 5-minute walk test) – patent applied for; (c) a population screening test for Atrial Fibrillation using pulse oximeter technology (patent protected), and (d) Bluetooth inhaler usage monitor.  
What is the intellectual property status of your innovation?:
IP is retained by respective companies within the Spirit Healthcare group of companies.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Kevin A. Auton 12/01/2017 - 10:55 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':

Converting Clinical lab based Xanthochromia procedure into Near Patient testing/Point of Care Procedure using pocket sized spectrometer.

Overview of Innovation:

I am thinking of converting Xanthochromia lab based spectrophotometry procedure (SAH/fatal accidents/Head injuries) into Point-of-care/Near patient testing (POCT) procedure. A small pocket sized spectrometer is going to come soon in the market.

The device is a molecular sensor with cloud based database. The company offers developmental tools to build the database, by scanning  every material that exists in this world..from paracetamol to material science. 

Converting this to POCT offer some advantages: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses themselves without much technical comptency can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:

Converting this to POCT offer some advantage: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:

Converting this to POCT offer some advantage: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Current and planned activity: 

Contacted the chief technology officer of the Company (Consumer physics) awaiting response for modifying the device into POCT medical diagnostic device. If green signal given may discuss with NHS trust and start the joint development/clinical trial/evaluation/validation/verification using NHS trust as base 

What is the intellectual property status of your innovation?:

N/A

Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
GANAESH 27/10/2016 - 01:21 Publish 1 comment
4
1
Votes
-99999
Innovation 'Elevator Pitch':
Incredible amounts of expensive drugs are thrown away by pharmaceuticals companies, health trusts & GP surgeries due to refrigeration problems. Everyware technology enables remote data monitoring & intervention for pharmaceutical & food storage
Overview of Innovation:
The problem. Correct handling and storage of drugs and medicines is critical in ensuring that they remain functional and safe to use. Regular monitoring and data capture highlights trends and issues not evident from manual record keeping. Over weekends and during holiday periods readings may not be recorded. Failure of a refrigerator or break in power supply could render contents unusable or remain undetected
 
EveryWare has developed an intelligent software platform with smart sensors, integrated and modular, in conjunction with clinicians to tackle this major problem. Local devices monitor a range of parameters, including ambient temperature, pressure and humidity; together with refrigeration temperatures at different levels within each unit
 
Local and remote alerts can be triggered when your own defined rules are breached. Alerts may be visual and audible in a monitored location with users receiving direct notifications via email, SMS and other channels. Data is visualized and accessible on computers, tablets and smartphones
 
Testimonial
Clinical bodies and Trusts’ guidelines require regular monitoring of critical storage temperatures. Legislation requires that records are kept and this is often a manual task with readings taken at up to 24 hour intervals
 
Successful trials yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7

Differences between types of refrigerator become evident. Recovery time following prolonged periods of access can expose the contents to raised temperatures for longer; trend data clearly demonstrates the effects of daily routines and identifies opportunities for training that will improve the safe storage and dispensing of critical medicines
 
EveryWare’s unique modular system means that the unit cost of the sensors is low. All other costs are capped, so no need to worry about data rates and variable costs. Annual cost of the system is a fraction of the cost of the assets or processes being monitored. System is designed from the ground up to be completely user-configurable to suit local and business requirements. Security is paramount; all cloud systems and data are network-isolated, multiple-passkey protected with encrypted communications.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Compliant drug storage
There is a legislative requirement to store critical medicines within specified parameters. Moreover, it is imperative that safe storage can be demonstrated and that only safe products are used.
 
Equally, any fault or disruption to the storage infrastructure doesn’t automatically render the products beyond safe use. Smart monitoring, reporting and validation afford peace of mind. Efficacy of the drugs can be evidenced and detect abnormal patterns of behaviour or access issues e.g. refrigerator door left open.
 
Broad clinical guidelines indicate that regular, period monitoring by technicians will suffice; often once every 24 hours and often not during weekends and holiday periods.
 
There are several risks with this approach that can render expensive drugs ineffective and worse still, fail to deliver the anticipated results. A power outage in the early hours or over a weekend may be masked by a reinstatement long before working hours. The damage may already be done if excessive temperatures have been realised.
 
The solution is to introduce smart monitoring with remote data logging and alerts. Continuous, electronic monitoring not only captures specific events 24/7 and raise alarms but provides valuable trend data. Battery backup will buffer mains failure without disruption to the monitoring or connectivity. Real time monitoring has clearly shown systematic issues occur out of working hours and variations within specific refrigerated facilities. Clinical practices will also affect the storage conditions; a feature that is evident from trend data. The effects of prolonged loading and unloading with the refrigerator open shows the impact upon refrigeration temperatures and the extended recovery time to achieve safe storage temperatures when eventually closed. Access to the refrigerators out of prescribed hours may also raise an alert if there is a security concern.
 
EveryWare has installed local monitoring systems in hospitals and clinical environments that are capable of tracking a range of critical conditions. Not just in refrigeration units but ambient conditions in key locations may be monitored through a common network. Within treatment, theatre, storage or living areas the network of wireless devices can track temperature, relative humidity and pressure along with other factors such as controlled access and refrigeration performance.
 
In homes EveryWare could be used with ambient and movement sensors to detect risk of hypothermia or falls.
 
Initial Review Rating
4.60 (2 ratings)
Benefit to WM population:
Overall benefits summary
Installations of the system have already demonstrated potential savings in recent trials.
  • Money saved by GP surgeries and health trusts through proper refrigeration of medicines
  • Money saved by pharmaceuticals companies through proper refrigeration 
  • Money saved by pharmaceuticals companies by not having to pre-emptively over-produce product to compensate for GP and trust wastage
  • Quality of patient care increases as a result of cost savings throughout the medicine supply chain
  • Meets strict legislative requirements ((strict environmental monitoring protocols are now required by CQC. Failure to comply requires drugs be destroyed at very high cost).
  • Modular (easy to add on additional ambient sensors, movements detectors etc)
  • Quick to install and upgrade
  • Predictive analytics software enables custom ‘rules based’ alerts to be created easily
  • Monitor multiple installations and multiple sensors from a single location (Dashboard)
     
Quality control
  • Constant monitoring of refrigeration and the ability to react instantly minimises the amount of wastage caused by medicine being spoiled by high temperatures. The unique modular design enables additional sensors to be quickly integrated. Predictive analytics software enables custom ‘rules based’ alerts and monitoring protocols to be easily created and monitored.
Legislation
  • The easy monitoring of temperatures makes it much easier to comply with the strict legislation imposed by health bodies such as the MHRA and CQC.
     
GP Surgeries
  • Surgeries and trusts are able to monitor the temperature of their drugs in the refrigerator and react instantly should parameters be broken.
     
Patient care
  • The cost savings made by reducing wastage can be channelled back into the healthcare system, improving overall patient care.
For more information see: http://www.everyware.uk.com/products/21st-century-drug-monitoring
Current and planned activity: 
Current Activity
Successful trials have been conducted with SWFT Clinical Services Ltd (a subsidiary of the South Warwickshire NHS Foundation Trust) which yielded a wealth of information for pharmacy staff to gain immediate, real time insight into how efficient their refrigerators are and how ambient conditions and working practices affect them.
 
Positive actions were taken to improve the effectiveness and avoid potential problems that might have occurred. Clinicians benefit from the reduced workload and the availability of high resolution data proves compliance with healthcare guidelines 24/7.
 
We have recently entered discussions with GP practice in Norfolk in response to CQC’s strict environmental monitoring requirement for drug storage.

Planned Activity
  • We would welcome NHS input in our systems design and further development
  • We wish to increase awareness within GP and CCGs
  • We are seeking additional trial sites
What is the intellectual property status of your innovation?:
All IP resides with the company
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Nigel Maris 18/10/2016 - 08:42 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
An engaging educational board game and HTML5 web app to help children with Cystic Fibrosis, and their families, to improve their understanding of the condition and how to manage it.
Overview of Innovation:
The game is designed to help children and families manage Cystic Fibrosis more effectively. Originally created by specialists at Coventry & Warwickshire Partnership NHS Trust to help healthcare professionals develop a more effective relationship with young patients and their families. The game was so effective that Focus Games Ltd was asked to redesign and streamline the game and make it available to a wider audience.

The game is designed for between 2 and 4 individual players (or small teams of players) who compete to move around the board answering CF-related questions and scenarios correctly. The game is very easy to play and doesn’t require a specialist facilitator; anyone can play the game. This makes it ideal for use in the home and at school with family, friends and schoolmates.
 
Objectives
To help young patients, their families and friends to improve their understanding of Cystic Fibrosis and to manage the condition more effectively.
 
A patient engagement tool for healthcare specialists to use:
  • Children with Cystic Fibrosis
  • Families & friends of CF patients
  • Schools
  • Public health awareness
Can be used in:
  • CF clinics
  • Other healthcare settings
  • At home
  • In school
The board game is very portable, the rules are very simple and specialist facilitation skills are not required so the game can be played by anybody in any setting.
 
The board game is competitive and accommodates up to 4 individual  players, or teams of players. Games last between 45 and 60 minutes.

The HTML5 web app is a simplified version of the board game designed for individuals to use on smartphones, tablets and desktop PCs. However, it can also be used with groups on tablets, screens and interactive whitebboards etc.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
The original game was developed by Coventry and Warwickshire Partnership NHS Trust and Focus Games Ltd has refined and reworked the game to make it more engaging and more likley to suceed as a commercial product. This process was supported byMidTECH Innovations (NHS Innovations West Midlands).

Benefits to the NHS include:  
  • Increased  knowledge of CF not just for the patient but for the whole family and improved engagement with the CF Team - This would help give children and young people a sense of control in managing their condition. Symptoms are recognised by CF patients and parents early and acted upon so infections are treated quickly therefore less time would be spent as in an inpatient making savings on bed space and staffing.
  • Increased understanding of treatments - Children can express and explore their fears and emotions in a safe place. Play provides the medium to help manage these feelings and therefore promotes resilience
  • Improved  compliance with treatment – Children and young people with CF will often have multiple treatment regimens to follow. The CF game gives an understanding of why particular treatments/medicines need to be adhered to. Compliance would mean improved and less stressful visits for treatments and hospital appointments where children are having to be persuaded  to comply with cough swabs/lung function tests etc. This can take up a considerable amount of time for nurses and Doctors both in the Community and the Hospital.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
All of the benefits that the game could deliver for the NHS would benefit the WM population. In addition the game has been developed by a WM NHS Trust and as such the publicity and any shared revenue will be focussed on the WM.
Current and planned activity: 
The original game was developed by Coventry and Warwickshire Partnership NHS Trust and Focus Games Ltd has refined and reworked the game to make it more engaging and more likley to suceed as a commercial product. This process was supported byMidTECH Innovations (NHS Innovations West Midlands).

The board game has been tested within the NHS and also by members of patient support groups. Feedback has been positive and we now wish to extend the scope of testing to cover a more sophisticated online version of the game and also to manufacture the board game.
What is the intellectual property status of your innovation?:
The IP is owned by Coventry and Warwickshire Partnership NHS Trust, and used by Focus Games Ltd under licence from them.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
This game is designed to be used anywhere in the UK, and possibly overseas. We have not yet secured the funding to launch the game commercially. However, we have launched many other games that are being used extensively in the UK and overseas so we are confident that the model works.
Measures:
The most practical measure will be the collection of qualitative feedback from users both patients, carers and healthcare professionals. This would include ongoing questions about any changes to lifestyle and treatement adeherence. This being done for many other existing games that we have published. We would also approach independent stakeholders and hope to encourage them to study the efficacy of the game.
Read more
Hide details
Andy Yeoman 24/08/2016 - 15:08 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
LiverMultiScan is an FDA 510(k) cleared and CE marked MRI technology that provides a quantitative assessment of liver health, including fibroinflammatory disease, steatosis and iron, all in a non-contrast 5 minute scan.
Overview of Innovation:
Perspectum Diagnostics is a medical imaging company with an ISO 13485 compliant CoreLab. The company has developed novel imaging technology, LiverMultiScan, an MRI-based non-invasive tool that has attained CE-marking and FDA 510(k) clearance to aid the diagnosis of patients with chronic liver disease.
LiverMultiScan (and LiverMultiScan Discover for clinical trial use) can characterise liver tissue in three ways, providing accurate measurements of liver fat, hepatic iron content and fibro-inflammatory disease, using the proprietary Liver Inflammation and Fibrosis (LIF) score. The LIF score has been shown to stratify NAFLD and NASH patients (Pavlides, 2015), correlate with histological markers of inflammation and fibrosis (Banerjee, 2014), and most importantly, is the first imaging test to predict liver-related clinical outcomes (Pavlides, 2016). It is the only liver imaging technology included in the UK Biobank study, with 100,000 scans to be performed in the coming years (Kelly, 2015).
Available as a Quantitative Analysis Service (QAS), LiverMultiScan has been cleared as an imaging tool to aid the diagnosis of early liver disease. It offers a standardised and high-quality method for supporting Gastroenterology/Hepatology and Radiology departments in diagnosis and monitoring of the liver in clinical settings and studies, and has potential to streamline clinical management by compressing the diagnostic pathway. Perspectum is also supporting multiple international clinical trials with LiverMultiScan Discover.
  • Banerjee et al. (2014) Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 60:69-77.
  • Kelly et al. (2015) Predicted prevalence of NAFLD and NASH in a large population using non-invasive multiparametric MRI. AASLD 2015. Abstract ID: 931.
  • Pavlides et al. (2015) Multi-parametric magnetic resonance can accurately assess NAFLD histological disease severity; comparison with transient elastography. AASLD 2015. Abstract ID: 2190.
  • Pavlides et al. (2016) Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 64:308-315.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Patient and medicines safety
Benefit to NHS:
The utility of LiverMultiScan for assessing fibroinflammatory disease, steatosis and predicting clinical outcomes means it is well-positioned to reduce (and potentially remove) the need to perform invasive liver biopsies. It also facilitates longitudinal monitoring, which is near impossible with current sampling technology.
According to a recent NIHR HTA report, the cost of a liver biopsy is £956, but this can increase significantly with complications (clinically significant bleeding in 1.1 – 1.6%). For healthcare providers, liver biopsies are unappealing because of the attendant risk, financial cost, lack of reliability (as sampling only 0.002% of the liver volume), and uncertainty in interpretation. Nevertheless, primarily because there has not been a viable alternative, it is estimated that 650,000 liver biopsies are performed annually worldwide. 
There are substantial costs associated with managing patients with NAFLD, in particular for those patients progressing to NASH who are at significant risk of cirrhosis, HCC and liver failure. Although pharmacologic options are limited, there are numerous clinical trials ongoing.
Available treatment options increase (e.g., diet, surgery), outcomes improve and healthcare costs decrease the earlier those with, or at risk of, more advanced disease are identified. When combined with the rising incidence of NAFLD and NASH, the availability of a non-invasive test for accurately assessing fibroinflammatory disease, steatosis and predicting clinical outcomes, is vital.
A recent health economic study (submitted for publication) from the University of Birmingham concluded that LiverMultiScan is cost effective either as an adjunct to or replacement of Fibroscan in the diagnostic pathway of NAFLD. In addition, the utility of LiverMultiScan in reducing the proportion of patients with suspected NAFLD undergoing hospital consultations and/or liver biopsies is currently being evaluated in a large Europe-wide multicentre clinical trial (including the UK).
LiverMultiScan could allow:
  • A faster throughput and diagnostic analysis than conventional sampling – reducing patient lists and identifying those that need and do not need clinical intervention.
  • Regular monitoring of patients without painful invasive and potentially dangerous biopsies.
  • A less traumatic assessment of liver disease in children.
  • Assessment of liver health in other diseases (e.g., viral hepatitis, alcoholic liver disease)
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Liver disease is the fifth ‘big killer’ in England and Wales, after heart, cancer, stroke and respiratory disease (http://www.britishlivertrust.org.uk/about-us/media-centre/facts-about-liver-disease), with twice as many people dying from liver disease now compared to 1991.
In a European study, the healthcare costs for patients with NAFLD were 26% higher than for those without the disease (Baumeister, 2008). In the US, the direct costs of cirrhosis and chronic liver disease were estimated to by $2.5 billion, whereas indirect costs were estimated to be $10.6 billion (Ruhl, 2008).
Identifying those with, or at risk of, more advanced liver disease earlier increases treatment options available, reduces healthcare costs and improves outcomes. Benefitting both the NHS and wider West Midlands community.
This diagnostic test could also be used to aid the diagnosis and monitoring of liver disease in children, with a European clinical trial underway.
 
  • Baumeister et al. (2008) Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology. 134:85.
  • Ruhl et al. (2008) Costs of digestive disease. In The Burden of Digestive Disease in the United States. NIH Publication. pp 137-143.
Current and planned activity: 
LiverMultiScan currently in use at University Hospitals in Birmingham, Edinburgh, Oxford Southampton & Kings College London (KCL). Discussions with other NHS sites

Recent completion of large Innovate UK funded 2.5 year study at University Hospitals Birmingham & Edinburgh to develop & validate against liver biopsy

KCL is UK site for large EU multi-centre clinical trial to evaluate cost-effectiveness of LiverMultiScan in primary care pathway.

Patient study - 100 patients with history of liver disease receive LiverMultiScan, nearing completion with extremely +ve feedback

LiverMultiScan is only liver imaging technology in UK Biobank - 100,000 subjects to be imaged

Planned activity
West Midlands location of choice as:
  • Build on relationship with University of Birmingham following 2.5 yr study
  • West Midland’s considerable expertise in liver disease
  • Large patient cohort and trials infrastructure
  • Involve Children’s Hospital in study
  • Dr Banerjee, founder & CEO, visiting Hon. Consultant Hepatologist at UHB
What is the intellectual property status of your innovation?:
Perspectum holds or exclusively licenses 7 patent applications in the UK and other territories. To date, one has been granted in the UK (GB2497668).
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Matt Kelly 03/08/2016 - 10:07 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':

We know that time in the NHS is precious, why waist time plugging in and charging devices when you can simply place the device on our stand. Don't lean over a tablet for lengthy periods; use our stand to alleviate posture issues, aches and pains.
Overview of Innovation:

Qlic is a Universal tablet stand with charging capabilities. Qlic has several models; cable suitable for both apple and android tablets, simply plug the charging cable into your device and plug the power supply unit to the wall. Our QI patch receiver can enable most devices for wireless charging. Insert the connecter to the charging point on your device, stick the patch to the rear and pop your tablet or phone back into its case (compatible with cases up to 5mm thick).

 Qlic was designed to save time for tablet users as well as to provide a more ergonomically suitable solution for people who use mobile devices on a daily basis.

​We believe that as mobile devices become more and more popular within care settings Qlic will help to support the working environment within NHS trusts.

​Qlic was originally developed to support the learning environment within schools and has proven to be very popular within educational settings (please see our product video - https://www.youtube.com/watch?v=Cepvxf07oU8).

After looking into the NHS and the use of mobile devices we thought that Qlic would be ideal for NHS settings as well. Not only will Qlic save time and effort, you won't need to think about charging the device as simply placing the device on the cradle will enable charging to begin. We looked at the use of mobile devices and thought that our stand would be ideal on nurses stations, for use by clinical leads, office staff, ambulances and drug trolleys as our stand can also be permanently fixed to surfaces. 

​We would like to find out the type of tablets/ mobile devices and the type of protective cases currently used to ensure that our stand is suitable for all. We would also like suggestions on where you think our product would be most suitable for use? Where would Qlic make your life easier?  



 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Digital health
Benefit to NHS:
  • Time and space saving.
  • Easier to view content on mobile devices.
  • Secure.
  • Enables the user to sit in the correct ergonomic position.
  • Ensures mobile devices are charged at all times.
  • Ensures mobile devices are easily accessible to users.
Initial Review Rating
2.80 (2 ratings)
Benefit to WM population:
Qlic will improve efficiency in the NHS settings within the west midlands by ensuring all mobile devices are fully charged at all times. Qlic will ensure that Staff will have one less thing to worry about with regards to daily use of mobile devices enabling more time spent on more important tasks and with patients. 
Current and planned activity: 
We are not currently involved with the NHS but are willing to undertake any developments needed.
What is the intellectual property status of your innovation?:
Patent pending on the cardle adjustment. The design is a registered design with the government IPO.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Katie Loforte 01/08/2016 - 10:43 Publish Login or Register to post comments
0
0
Votes
-99999
Initial Review Rating
3.93 (3 ratings)
Read more
Hide details
Anonymous 12/05/2016 - 10:36 Deleted 1 comment

Active Campaigns